MLN4924, a Novel Investigational Inhibitor Of NEDD8-Activating Enzyme (NAE), In Adult Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Results From Multiple Dosing Schedules In a Phase 1 Study
Publication
, Conference
DeAngelo, DJ; Erba, HP; Maris, MB; Swords, RT; Anwer, F; Altman, JK; Hua, Z; Blakemore, SJ; Faessel, H; Dezube, BJ; Medeiros, BC
Published in: Blood
November 15, 2013
Duke Scholars
Published In
Blood
DOI
EISSN
1528-0020
ISSN
0006-4971
Publication Date
November 15, 2013
Volume
122
Issue
21
Start / End Page
1443 / 1443
Publisher
American Society of Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
DeAngelo, D. J., Erba, H. P., Maris, M. B., Swords, R. T., Anwer, F., Altman, J. K., … Medeiros, B. C. (2013). MLN4924, a Novel Investigational Inhibitor Of NEDD8-Activating Enzyme (NAE), In Adult Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Results From Multiple Dosing Schedules In a Phase 1 Study. In Blood (Vol. 122, pp. 1443–1443). American Society of Hematology. https://doi.org/10.1182/blood.v122.21.1443.1443
DeAngelo, Daniel J., Harry P. Erba, Michael B. Maris, Ronan T. Swords, Faiz Anwer, Jessica K. Altman, Zhaowei Hua, et al. “MLN4924, a Novel Investigational Inhibitor Of NEDD8-Activating Enzyme (NAE), In Adult Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Results From Multiple Dosing Schedules In a Phase 1 Study.” In Blood, 122:1443–1443. American Society of Hematology, 2013. https://doi.org/10.1182/blood.v122.21.1443.1443.
DeAngelo DJ, Erba HP, Maris MB, Swords RT, Anwer F, Altman JK, et al. MLN4924, a Novel Investigational Inhibitor Of NEDD8-Activating Enzyme (NAE), In Adult Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Results From Multiple Dosing Schedules In a Phase 1 Study. In: Blood. American Society of Hematology; 2013. p. 1443–1443.
DeAngelo, Daniel J., et al. “MLN4924, a Novel Investigational Inhibitor Of NEDD8-Activating Enzyme (NAE), In Adult Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Results From Multiple Dosing Schedules In a Phase 1 Study.” Blood, vol. 122, no. 21, American Society of Hematology, 2013, pp. 1443–1443. Crossref, doi:10.1182/blood.v122.21.1443.1443.
DeAngelo DJ, Erba HP, Maris MB, Swords RT, Anwer F, Altman JK, Hua Z, Blakemore SJ, Faessel H, Dezube BJ, Medeiros BC. MLN4924, a Novel Investigational Inhibitor Of NEDD8-Activating Enzyme (NAE), In Adult Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Results From Multiple Dosing Schedules In a Phase 1 Study. Blood. American Society of Hematology; 2013. p. 1443–1443.
Published In
Blood
DOI
EISSN
1528-0020
ISSN
0006-4971
Publication Date
November 15, 2013
Volume
122
Issue
21
Start / End Page
1443 / 1443
Publisher
American Society of Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology